Lipinski's Rule of Five Information & Lipinski's Rule of Five Links at HealthHaven.com
advertise
add site
services
publishers
database
health videos
Bookmark and Share

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 
about
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN

Lipinski's Rule of Five is a rule of thumb to evaluate druglikeness, or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most medication drugs are relatively small and lipophilic molecules.[1]

The rule describes molecular properties important for a drug's pharmacokinetics in the human body, including their absorption, distribution, metabolism, and excretion ("ADME"). However, the rule does not predict if a compound is pharmacologically active.

The rule is important for drug development where a pharmacologically active lead structure is optimized step-wise for increased activity and selectivity, as well as drug-like properties as described by Lipinski's rule. The modification of the molecular structure often leads to drugs with higher molecular weight, more rings, more rotatable bonds, and a higher lipophilicity.[2]

Lipinski's rule says that, in general, an orally active drug has no more than one violation of the following criteria:

Note that all numbers are multiples of five, which is the origin of the rule's name.

Contents

[edit] Improvements

To evaluate druglikeness better, the rules have spawned many extensions, for example one from a 1999 paper by Ghose et al.:[3]

  • Partition coefficient log P in -0.4 to +5.6 range
  • Molar refractivity from 40 to 130
  • Molecular weight from 160 to 480
  • Number of atoms from 20 to 70

Over the past decade Lipinski's profiling tool for druglikeness has led to further investigations by scientists to extend profiling tools to lead-like properties of compounds in the hope that a better starting point in early discovery can save time and cost.

[edit] See also

[edit] References

  1. ^ C.A. Lipinski; F. Lombardo; B.W. Dominy and P.J. Feeney (1997). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Adv Drug Del Rev 23: 3–25. doi:10.1016/S0169-409X(00)00129-0. 
  2. ^ T. I. Oprea, A. M. Davis, S. J. Teague, P. D. Leeson (2001). "Is There a Difference between Leads and Drugs? A Historical Perspective". J. Chem. Inf. Comput. Sci. 41: 1308–1315. doi:10.1021/ci010366a. 
  3. ^ Arup K. Ghose, Vellarkad N. Viswanadhan, and John J. Wendoloski (1999). "A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery". J. Combin. Chem. 1: 55–68. doi:10.1021/cc9800071. 

[edit] External links




Product Results (view all...)

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 



↑ top of page ↑about thumbshots